Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Sell
25
AQST Quote, Financials, Valuation and Earnings
Last price:
$2.95
Seasonality move
:
9.3%
Day range:
$2.52 - $2.67
52-week range:
$2.24 - $6.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.98x
P/B ratio:
--
Volume:
1.3M
Avg. volume:
1.9M
1-year change:
-46.56%
Market cap:
$261M
Revenue:
$57.6M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingAquestive Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.86, Aquestive Therapeutics has an estimated upside of 273.53% from its current price of $2.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.75 representing -79.92% downside risk from its current price of $2.64.
Fair Value
-
According to the consensus of 5 analysts, Aquestive Therapeutics has 273.53% upside to fair value with a price target of $9.86 per share.
AQST vs. S&P 500
-
Over the past 5 trading days, Aquestive Therapeutics has underperformed the S&P 500 by -0.41% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Aquestive Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Aquestive Therapeutics revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Aquestive Therapeutics reported revenues of $11.9M.
Earnings Growth
-
Aquestive Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Aquestive Therapeutics reported earnings per share of -$0.19.
Enterprise value:
222M
EV / Invested capital:
-8.03x
Price / LTM sales:
3.98x
EV / EBIT:
--
EV / Revenue:
3.86x
PEG ratio (5yr expected):
-0.02x
EV / Free cash flow:
-6.18x
Price / Operating cash flow:
21.16x
Enterprise value / EBITDA:
120.22x
Gross Profit (TTM):
$39.7M
Return On Assets:
-42.77%
Net Income Margin (TTM):
-76.68%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-114.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $47.7M | $50.6M | $57.6M | $13.2M | $11.9M | |
| Gross Profit | $28.3M | $29.8M | $39.7M | $8.5M | $7.3M | |
| Operating Income | -$42.1M | -$15.1M | -$30.8M | -$3.9M | -$13.6M | |
| EBITDA | -$39.6M | $1.2M | -$26.6M | -$4.3M | -$12.7M | |
| Diluted EPS | -$1.14 | -$0.15 | -$0.52 | -$0.13 | -$0.19 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $44.6M | $47.3M | $39.9M | $41M | $88.2M | |
| Total Assets | $62.9M | $62M | $57.1M | $57.4M | $101.4M | |
| Current Liabilities | $21.1M | $22M | $39.5M | $18.3M | $18.9M | |
| Total Liabilities | $111.4M | $144.1M | $175.6M | $163.9M | $161.6M | |
| Total Equity | -$48.5M | -$82.1M | -$118.6M | -$106.5M | -$60.2M | |
| Total Debt | $36.9M | $53.6M | $52.1M | $27.5M | $32.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$9.8M | -$6.4M | -$35.8M | -$4.9M | -$6.5M | |
| Cash From Investing | -$2.5M | -$995K | -$159K | -$16K | -$15K | |
| Cash From Financing | $11.6M | $4M | $83.6M | $3.9M | $157K | |
| Free Cash Flow | -$12.3M | -$7.4M | -$35.9M | -$5M | -$6.5M | |
AQST
Sector
Market Cap
$261M
$36.4M
Price % of 52-Week High
42.38%
45.1%
Dividend Yield
0%
0%
Shareholder Yield
-25.33%
-0.74%
1-Year Price Total Return
-46.56%
-39.83%
Beta (5-Year)
2.762
0.773
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$2.70
200-day SMA
Sell
Level
$3.78
Bollinger Bands (100)
Sell
Level
2.97 - 4.83
Chaikin Money Flow
Sell
Level
-49.5M
20-day SMA
Sell
Level
$2.92
Relative Strength Index (RSI14)
Sell
Level
40.08
ADX Line
Sell
Level
22.22
Williams %R
Neutral
Level
-75
50-day SMA
Sell
Level
$3.11
MACD (12, 26)
Sell
Level
-0.15
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Sell
Level
-18.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.3064)
Sell
CA Score
(Annual)
Level (-8.8446)
Buy
Beneish M-Score
(Annual)
Level (-3.1611)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (8.6077)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (5)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Stock Forecast FAQ
In the current month, AQST has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AQST average analyst price target in the past 3 months is $9.86.
-
Where Will Aquestive Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Aquestive Therapeutics share price will rise to $9.86 per share over the next 12 months.
-
What Do Analysts Say About Aquestive Therapeutics?
Analysts are divided on their view about Aquestive Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Aquestive Therapeutics is a Sell and believe this share price will drop from its current level to $4.75.
-
What Is Aquestive Therapeutics's Price Target?
The price target for Aquestive Therapeutics over the next 1-year time period is forecast to be $9.86 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AQST A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Aquestive Therapeutics is a Buy. 5 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AQST?
You can purchase shares of Aquestive Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Aquestive Therapeutics shares.
-
What Is The Aquestive Therapeutics Share Price Today?
Aquestive Therapeutics was last trading at $2.95 per share. This represents the most recent stock quote for Aquestive Therapeutics. Yesterday, Aquestive Therapeutics closed at $2.64 per share.
-
How To Buy Aquestive Therapeutics Stock Online?
In order to purchase Aquestive Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Does Intel Stock Have Room to Grow?
Intel Corporation (NASDAQ:INTC)’s recent innovations, Xeon 6 SoC and Xeon®…
Is Walmart the Largest Retailer in the World?
For many years, Walmart (NYSE:WMT) has been the world’s largest…
Stock Ideas
Sell
49
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
44
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
45
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
50
GH alert for Mar 12
Guardant Health [GH] is up 1.1% over the past day.
Sell
44
TER alert for Mar 12
Teradyne [TER] is down 0.36% over the past day.
Buy
57
LMB alert for Mar 12
Limbach Holdings [LMB] is down 4.39% over the past day.
